Omeros (NASDAQ: [[ticker:OMER]]), the Seattle-based biotech company, said today it has completed its acquisition of drug discovery technology from Toronto-based Patobios. The assay technology from Patobios is supposed to help Omeros design new drugs against targets known as G-protein coupled receptors. The GPCR program is thought to be promising because many of the world’s top pharmaceuticals are currently aimed at GPCRs, and there are still an estimated 120 of these targets that are inaccessible by drugs today. Omeros raised $25 million last month from Paul Allen’s Vulcan Capital and the Washington Life Sciences Discovery Fund to support this scientific work.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
